Organ-on-chips Market Size & Share 2025 - 2034

Organ-on-chips Market Size

The global organ-on-chips market was valued at USD 147 million in 2024. The market is expected to reach from USD 201.5 million in 2025 to USD 2.1 billion in 2034, growing at a CAGR of 29.7% during the forecast period. The high market growth is attributed to the increasing need for replacing tests conducted on animals, continuous advancements in microfluidics and tissue engineering, rising focus on personalized medicine and drug development, and surging need for cost-effective and faster drug screening models, among other contributing factors.

The growing global burden of chronic diseases, such as cardiovascular disorders, malignancies, diabetes, and respiratory conditions, is a major contributor to the market as they require more sophisticated and tailored drug testing, as well as disease modeling tools. There is a global increase in these conditions which has resulted in mitigating the need for more advanced research tools like organs-on-chips (OoC) which can simulate human organ in vitro to advance the research infrastructure. According to the World Health Organization (WHO), noncommunicable diseases (NCDs) kill 41 million people each year, equivalent to 74% of all deaths globally. Each year, more than 15 million people die from NCD between the ages of 30 and 69 years; 85% of these premature deaths occur in low- and middle-income countries.
 

Moreover, the increasing need for personalized medicine also contributes greatly to the development of organs-on-chips (OoC) technologies, as these systems provide tailored analyses of drug responses, patient-specific disease mechanisms, and acute individualizations. Personalized medicine endeavors to optimize the treatment strategy to the patient’s genetic and molecular characteristics, and OoCs are far better than customary in vitro models since they replicate human organ functions more accurately.
 

Organ-on-chips (OoCs) are advanced microfluidic devices capable of recreating the form and function of human organs at a small scale using human cells cultured in controlled conditions. These chips mimic physical behaviors including blood circulation, mechanical pressure, and cellular activities, enabling precise studies of organ functions, disease progression, and the impact of drugs on the body. Organ-on-chip technology provides a novel approach to replace testing on living organisms, granting a more pertinent platform for testing drugs, assessing their toxicity, and conducting biomedical research, which may improve precision while decreasing expenditures.
 

Organ-on-chips Market Trends

The organ-on-chips (OoC) market is witnessing emerging trends which expand its usage and accelerating its adoption in research and development. Primarily due to the ever-growing technology on artificial intelligence in healthcare and machine learning, organ-on-chip technology is rapidly advancing. Automated systems are now able to deliver thorough analysis of the complex cellular antics to microminiature organ systems, making it easier for scientist to evaluate and make predictions on the effects of certain drug procedures on the systems.
 

• Additionally, multi-organ chips are of particular value in studying complex organ pathologies such as cancers, diabetes mellitus, and other cardiovascular conditions, which involve an interplay of several organ systems and require a multi-faceted approach for feasible disease management. The capacity to simulate these interactions is expected to aid in validating combination therapies while decreasing the dependence on animal models, which is in accordance with the increasing regulatory and humane requirements to find substitutes for animal testing.
   
• The use of organ-on-chip models that are tailored to individual patients is gaining traction due to the shift towards personalized medicine. These patient-derived cells enable the construction of chips that recapitulate the biological features of the patient, permitting customized medicine through precise drug-testing and therapy pathways optimization. This is especially important for cancer treatment where individualized care is paramount, contributing to the growing market demand.
   

Trump Administration Tariffs

• President Trump's administration implemented tariffs on imports, including China and other countries, which may tremendously impact the medical device industry in the U.S., including the growing organs-on-chips sector. These tariffs may cause broader taxes on an array of medical equipment and devices such as the various components that manufacturers depended on.
   
• For example, businesses may face high costs for basic components such as electronic parts and specialty materials needed for sophisticated biomedical devices manufacturing processes, specifically organs-on-chips.
   
• In addition, the tariffs will also impose new costs on the established supply chains, forcing many companies to look for alternative suppliers of their constantly employed parts or move their manufacturing altogether. These kinds of shifts are extremely difficult in specialized niches such as organs-on-chips, where perfectly reliable and sophisticated parts are needed to emulate human organ functions.
   
• The added operational expenses coupled with the uncertainty created by the tariffs may also stalls overall advance development within this burgeoning ecosystem.
   
• The impact of these trade policies will reveal the extent of the susceptibility of the U.S. medical device industry to global supply chain interruptions and demonstrated the need for strategic foresight to prevent such issues in the future.
   

Organ-on-chips Market Analysis

Based on type, the market is classified into products and services. The products segment is further bifurcated into liver-on-chip, lung-on-chip, heart-on-chip, kidney-on-chip, and other products. The products segment generated the highest revenue of USD 110.8 million in 2024.
 

• The product market has several key factors that increase the demand for various products, including liver-on-chip, lung-on-chip, heart-on-chip, kidney-on-chip and many others. To begin with, the increasing prevalence of chronic diseases has created a greater need for more sophisticated drug testing, which is able to mimic human organs on a physiological level. As pharmaceutical companies work towards harnessing more resources but shortening the time it takes to develop a drug, OoC technologies presents great promise in comparison to popular used methods, which tend to take a lot of time and are unreliable.
   
• In addition, modern microfluidic technologies have improved organ-on-chip devices, making them more useful and reliable for research and development purposes. The National Institutes of Health (NIH) reported a 35% increase in funding for microfluidics and organ-on-chip technologies from 2021 to 2023.
   
• Similarly, many research institutions and biotechnology firms collaborate together which in turn has spurred innovation. The FDA claimed that more than 200 organ-on-chip validation studies were accomplished in 2022-2023. The European Medicines Agency reported a 45% growth in the usage of organ-on-chips for drug testing from 2021 to 2024 which in turn fosters growth for this segment.
   

Based on material, the organ-on-chips market is classified into polydimethylsiloxane (PDMS), polymer glass, and other materials. The polydimethylsiloxane (PDMS) segment dominated the market in 2023 with a market share of 42.9%.
 

• PDMS is known for its exceptional biocompatibility, ease of fabrication, optical transparency, and other properties in organ-on-chip (OoC) systems. Its PDMS use for microfabrication is expanding with the growing need for accurate in vitro human organ models for mimicry and PDMS is an easy to use option as it can be manufactured into any shape with precision.
   
• In addition, improved methods of PDMS fabrication, including soft lithography, have enhanced the reproducibility and scalability of OoC technologies. These advances have been seized by companies and research institutions to design sophisticated organ systems, including lung, liver, and heart models, which maintain and replicate more complex physiological conditions.
   
• The rising prevalence of chronic illnesses alongside an increased focus on tailored medicine are factors driving the PDMS-based OoC devices due to better testing models for drugs and modeling of diseases. The yearly overall increase for PDMS in the OoC market is estimated CAGR of 26.7%, indicating the importance of PDMS alongside advancing bio-research and discovering new medical drugs.
   

Based on model type, the organ-on-chips market is segmented into single organ model and multi-organ model. The single organ model segment dominated the market in 2024 and is anticipated to reach USD 1.1 billion by the end of forecast period.
 

• With these models, researchers are able to examine specific organ functions, tailoring focus to particular pathological processes or responses to drugs. The ease of manufacturing and maintenance associated with single-organ chips makes them ideal for the initial stages of testing before progressing to more intricate multi-organ systems.
   
• Moreover, single-organ models such as the heart, lung, liver or kidney, are preferred more accurate replicas and allow researchers to closely examine the targeted therapeutic effects and titration of a drug’s toxicity. The single-organ models also provide more targeted microenvironments for disease processes and drug action to be studied.
   
• The increasing supply of tailored medicine and drug screening, combined with microfluidics and tissue engineering, has suppressively supported the growth of this segment. The universal acceptance of single-organ models in pharmaceutical research that values simplicity and efficiency has also been an essential contributor.
   

Based on application, the organ-on-chips market is segmented into drug discovery, disease modelling, toxicity testing, personalized medicine, and other applications. The drug discovery segment dominated the market in 2024 and is anticipated to reach USD 657.3 million by the end of forecast period.
 

• The demand for more accurate and efficient preclinical models is organ-on-chip technology (OoCs) allows for more precise drug testing and less dependency on outdated animal testing. These microscale devices offer organs-on-chips and more realistic OoCs simulacra human organs and allow easier predictions for pharmaceutical firms on human body reactions to medications, thus minimizing losses resulting from late-stage clinical trial failures.
   
• The rising complexity of drug compounds and the high attrition rates in drug development make it more imperative than ever to maximize the screening provided by OoCs for both drug efficacy and toxicity. OoCs provide in vitro models that replicate pathophysiological states at the organ level, which significantly enhances the relevance of the information generated during drug discovery. Regulatory authorities such as the FDA have conveyed increasing readiness to rely on data produced with this technology due to its capacity to furnish vital human-relevant information capable of improving the drug approval process.
   
• An overview of the capabilities and limitations of OoCs in drug discovery is seen from the partnership between Emulate Inc. and other big pharmaceutical companies. Emulate’s Organ-Chips have been used in more than 150 laboratories, which include 17 out of 25 global biopharmaceuticals and the FDA for COVID-19 therapeutic and vaccine evaluations. They have even been used in space-based research, which showcases their broad applicability and dependability.
   
• In addition, the body's organs-on-chips technology is expanding rapidly, driven primarily by the drug discovery segment. This segment is growing due to heightened research funding and the adoption of OoC systems by capital pharmaceutical companies which seek to improve efficiencies associated with drug development timelines and costs.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the organ-on-chips market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and other end users. The pharmaceutical and biotechnology companies segment dominated the market in 2024 and is anticipated to reach USD 1.4 billion by the end of forecast period.
 

• This segment is mainly driven by the increasing needs of the healthcare industry regarding the processes involved in the creation and development of novel drugs. To reduce the need for animal testing, pharmaceutical companies are using organs-on-chips technology to develop more precise human tissues models and simulate physiological responses to various drugs and other stimuli.
   
• In addition, the escalating number of patients suffering from chronic diseases and the growing demand for personalized medicine are key factors contributing to the investment in this technology. Along with these factors, the other contributors are the developments in microfluidics and tissue engineering, which are made possible by these new advanced technologies.
   
• Emulate Inc and AstraZeneca, among other pharmaceutical companies, form new partnerships which emphasize the adoption of organs-on-chips for drug testing purposes in their primary workflows. Also, these technologies are starting to be understood by global regulatory bodies which may allow bypassing some of the bureaucratic red tape used in new drug approvals.
   
• Therefore, a cumulative tendency for pharmaceutical and biotechnological companies to embrace organs-on-chips technology, thus expanding the market and revolutionizing conventional methodologies utilized for drug development and discovery. The targeted enhancement of operational efficiency in research and development places them strategically with regard to leadership in biopharmaceuticals innovative technology development in the near future.

U.S. organ-on-chips market accounted for USD 56.9 million in 2024. The U.S. dominated the global market in 2023 with USD 42.6 million growing from USD 30.8 million in 2022 and is anticipated to grow at a CAGR of 28.6% between 2025 to 2034 period.
 

• The organ-on-chip (OoC) market in the U.S. is booming because of extensive investment in biomedical research, developed technology infrastructure, and a friendly regulatory framework. There is a substantial Government and Private sector funding in the U.S. for the research of alternative methods to animal testing, spearheaded by the ethical and financial burdens alongside preclinical models.
   
• The National Institutes of Health (NIH) is one of the organizations that offers funding for OoC projects because of the possible enhancements technology can bring to precision in drug discovery and reduction of failures in late-stage trials.
   
• Moreover, U.S. biotech and pharmaceutical companies are quick to adopt new systems, which boosts the market further. The FDA’s use of OoC for assessing drug safety and efficacy has helped facilitate the integration of these systems by many companies, enabling the U.S. to dominate the global OoC market.
   

UK organ-on-chips market in the Europe is projected to grow remarkably in the coming years.
 

• In the UK, the government strongly supports the life sciences industry and the reduction of animal testing, which helps the OoC market. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has shown interest in alternative preclinical models, which supports the use of OoC technology. Programs funded by centers like UK’s National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) seek to improve testing OoC technology’s alternatives to animal testing.
   
• In addition, some British universities and biotech companies work together to advance research in disease modeling, in-vitro toxicology testing, and personalized medicine using OoC. There is also strong demand in these areas to improve the drug development pipeline and healthcare outcomes, which requires more human prescriptive models.
   

China holds a dominant position in the Asia Pacific organ-on-chips market.
 

• The market in China is undergoing rapid expansion owing to massive government spending on biotechnology and an increasing emphasis on sophisticated healthcare technologies. China's national healthcare plan prioritizes the assimilation of new technologies, and organ-on-chip systems are considered instrumental in modernizing drug development and disease research.
   
• The OoC technology is further supplemented by The China Precision Medicine Initiative which collects vast amounts of genomic data and allows researchers to build specified chips tailored to the genes provided, enhancing personalized treatment methodologies.
   
• In addition, strategic alliances are being formed by Chinese biotech companies with foreign counterparts to capitalize on advanced expertise while greatly enhancing local production capabilities. Boosting domestic spending on research and development and the focus on ethical alternatives to animal testing further strengthens China's position as a dominant competitor in the global OoC market.
   

Brazil organ-on-chips market in the Latin America is projected to grow remarkably in the coming years.
 

• Brazil is witnessing vigorous growth in its organ-on-chip market, owing to developments in biotechnology and a focus shift towards personalized medicine. These microdevices actually replicate the structures and functions of human organs, which make drug testing and disease modeling significantly easier relative to traditional methods.
   
• Organ-on-chip technology is being increasingly integrated into the pharmaceutical and research sectors in Brazil for drug testing as well as disease modeling. There has been growing demand due to the lack of efficient preclinical models which have been solved by organ-on-chip devices and human surrogate support.


• In addition, there is a growing concern for finding alternatives to animal testing due to ethical and regulatory considerations. Organ-on-chip technologies provide a more accurate testing platform while also being ethical, which would justify their implementation in Brazil while supporting global trends.
   

Organ-on-chips Market Share

The key players in the market such as Emulate, Axosim, TissUse GmbH, MIMETAS, and Nortis Inc., account for approximately 60% of the total market share, underscoring their strong influence on the organ-on-chips (OoC) landscape. The market is marked by rapid technological advancements and frequent new product introductions aimed at enhancing physiological relevance and research efficiency. Pharmaceutical companies and research institutions are increasingly integrating OoC devices into their workflows to improve the accuracy of drug discovery, accelerate preclinical testing, and reduce the high costs associated with failure in traditional models. Furthermore, the rising focus on personalized medicine is driving demand for customized OoC systems that reflect individual patient biology, further expanding the market’s scope.
 

Organ-on-chips Market Companies

Prominent players operating in the organ-on-chips industry include:

• Altis Biosystems
• AlveoliX
• Axosim
• Beonchip
• Bi/ond Solutions
• Cherry Biotech
• CN Bio Innovations
• Emulate
• Hesperos
• InSphero
• MesoBioTech
• Mimetas
• NETRI
• React4Life
• TissUse
   
• Emulate is a pioneer in the organ-on-chip space, known for its proprietary Human Emulation System, which models human biology with unparalleled physiological relevance. It collaborates extensively with pharmaceutical giants and regulatory bodies like the FDA to drive adoption in drug development and safety testing.
   
• Mimetas offers the OrganoPlate, a high-throughput, membrane-free organ-on-a-chip platform that enables 3D tissue culture and perfusion in a scalable format. Its strength lies in combining automation-friendly formats with complex co-culture capabilities, making it ideal for industrial drug screening.
   
• Axosim specializes in nerve-on-a-chip and brain-on-a-chip platforms, delivering unique models for neurotoxicity and neurodegeneration studies. Its focus on neural applications provides pharmaceutical companies with more predictive alternatives to animal testing in CNS drug development.
   

Organ-on-chips industry News

• In October 2024, Alveolix announced to be part of the PANC-CKI consortium, led by CasInvent Pharma. This project aims to develop a novel CK1 inhibitor for pancreatic cancer treatment, utilizing AI-driven digital twins, patient-derived organoids, and AlveoliX ‘s organs-on-chip technology.
   
• In September 2024, Emulate Inc launched its new Chip-R1 Rigid Chip, designed with low-drug-absorbing plastics to reduce compound absorption and improve biological modeling accuracy. Building on the company’s core Organ-Chip microfluidic design, the Chip-R1 enhances predictive drug response capabilities. This innovation supports more complex research applications, expanding Emulate’s potential in precision medicine, rare disease studies, and personalized therapies.
   
• In October 2023, AxoSim, Inc. announced completion of its acquisition of the microBrain-associated assets of Vyant Bio’s StemoniX subsidiary. The StemoniX acquisition includes the microBrain drug discovery platform, a 14,000 square foot research and development and manufacturing facility near Minneapolis, nine patents and associated intellectual property, and veteran scientists who helped develop microBrain technology and are experts in its application.
   

The organ-on-chips market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Products
  • Liver-on-chip
  • Lung-on-chip
  • Heart-on-chip 
  • Kidney-on-chip
  • Other products
• Services

Market, By Material

• Polydimethylsiloxane (PDMS)
• Polymer
• Glass
• Other materials

Market, By Model Type

• Single organ model
• Multi-organ model

Market, By Application

• Drug discovery
• Disease modeling
• Toxicity testing
• Personalized medicine
• Other applications

Market, By End Use

• Pharmaceutical and biotechnology companies
• Academic and research institutes
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE